comparemela.com

Latest Breaking News On - Biosciences investor contact - Page 8 : comparemela.com

HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM

/PRNewswire/ Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and.

Jeffreym daynoLuis sanayCompany nasdaqExchange commissionPrnewswire harmony biosciences holdings incParagon biosciencesBiosciences holdingsChief executive officerHarmony biosciencesPlymouth meetingPrivate securities litigation reform actAnnual reportBiosciences investor contactBiosciences media contact

Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates

01.08.2023 - WAKIX (pitolisant) Net Revenue Increased ~25% Year-over-Year to $134.2 Million for Second Quarter 2023 Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,450 for Second Quarter 2023 Exited Second Quarter 2023 With ~5,600 .

United statesJeffreym daynoLuis sanayExchange commissionMillion share repurchase programCompany updatesDrug administrationCompany nasdaqHarmony biosciences holdings incParagon biosciencesCompleted enrollmentTopline dataFourth quarterInitiate prader willi syndromeDirectors authorizedShare repurchase

HARMONY BIOSCIENCES ENTERS INTO $185 MILLION TERM LOAN FACILITY

PLYMOUTH MEETING, Pa., July 27, 2023 /PRNewswire/ Harmony Biosciences Holdings, Inc. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with.

Luis sanayJeffreym daynoPrnewswire harmony biosciences holdings incParagon biosciencesExchange commission onExchange commissionCompany current report on formJpmorgan chase bankBiosciences holdingsCurrent reportChase bankHarmony biosciencesPlymouth meetingPrivate securities litigation reform actAnnual reportBiosciences investor contact

HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION

PLYMOUTH MEETING, Pa., July 20, 2023 /PRNewswire/ Harmony Biosciences Holdings, Inc. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with.

United statesKumar budurLuis sanayParagon biosciencesPrnewswire harmony biosciences holdings incDrug administrationExchange commissionBiosciences holdingsChief medical officerFull prescribing informationHarmony biosciencesPlymouth meetingPrivate securities litigation reform actAnnual reportBiosciences media contactBiosciences investor contact

HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS ON AUGUST 1, 2023

PLYMOUTH MEETING, Pa., July 18, 2023 /PRNewswire/ Harmony Biosciences Holdings, Inc. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients.

Luis sanayPrnewswire harmony biosciences holdings incCompany nasdaqParagon biosciencesBiosciences holdingsHarmony biosciencesPlymouth meetingBiosciences investor contactBiosciences media contact

vimarsana © 2020. All Rights Reserved.